Register
Login:
Share:
Email Facebook Twitter


ETF Investing made simple; CEO of justETF explains why


Avacta Share Chat (AVCT)



Share Price: 68.00Bid: 67.00Ask: 69.00Change: 0.00 (0.00%)No Movement on Avacta
Spread: 2.00Spread as %: 2.99%Open: 68.00High: 68.00Low: 68.00Yesterday’s Close: 68.00


Share Discussion for Avacta


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Wisheyedbortum
Posts: 581
Observation
Opinion:Hold
Price:90.50
Finncap
13 Nov '16
Finncap reckons that Avacta's share price could more than double over the next year.
 
DD77
Posts: 180
Off Topic
Opinion:No Opinion
Price:94.00
RE: Over sold
3 Nov '16
Agreed. Pharmaceuticals are a slow burner though
Trader4Pay
Posts: 33
Off Topic
Opinion:No Opinion
Price:92.50
Over sold
2 Nov '16
avct us very over sold so could see 1.50 soon. Three to six months is my estimate but could be sooner
Trader4Pay
Posts: 33
Off Topic
Opinion:No Opinion
Price:93.00
Storey building
2 Nov '16
Yep great news me have 28k @ fracrion above one pound. Love to add but this amount could grow considerably. I do predict a take over and may be a bidding war. Lets take it one step at a time
sukithedog
Posts: 694
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:92.50
RE: News getting better and better
2 Nov '16
Major, I've got £50,000 worth at £1.15 average
Very happy to hold
wintzy
Posts: 397
Off Topic
Opinion:No Opinion
Price:91.50
RE: News getting better and better
2 Nov '16
I can't believe the buying opportunity here.
sukithedog
Posts: 694
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:91.50
News getting better and better
2 Nov '16
02 November 2016

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Avacta announces CAR-T cell therapy research collaboration with major US cancer centre

· CAR-T cell therapy is a major new area of cancer therapy that has attracted $billions of investment in the past few years

· Affimer technology will potentially provide significant advantages over antibody fragment technology currently used in CAR-T cell modification

· Proof-of-concept study with major US cancer centre has the potential to open up highly valuable licensing and partnering opportunities

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, today announces a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta's Affimer technology in novel CAR-T cell-based immunotherapy.

CAR-T immunotherapy is a form of cancer treatment in which the patient's own immune system T cells are modified to give them greater potency with which to attack cancer cells (see Notes). Treatments using these engineered immune cells have generated promising responses in patients with advanced cancers and CAR-T immunotherapy has become an intense area of research, clinical development and investment.

The simple structure and biophysical properties of Affimers potentially provide significant advantages over antibody fragment technology currently used in CAR-T cell modification and the collaboration announced today is intended to demonstrate a new class of CAR-T cell therapy that incorporate Affimer molecules.

The collaboration will be led by Renier J. Brentjens, MD, PhD, Director of Cellular Oncology at Memorial Sloan Kettering Cancer Center in New York.

As part of the collaboration Avacta will develop Affimer molecules that bind different regions of CD19, a surface protein specific to B-cells involved in lymphomas. Dr Brentjens' team will construct CAR-T cells incorporating these Affimer molecules and test their anti-tumour function in vitro and in in vivo animal efficacy models.

Under the terms of the agreement the ownership of the results generated directly as part of this collaboration will be shared between Avacta and MSK.

Alastair Smith, Avacta Group Chief Executive commented: "CAR-T cell therapy is an emerging and very exciting area of immuno-oncology which holds enormous clinical potential. We are delighted to be working with a world-leading team in the field to demonstrate the benefits that Affimer technology could bring to CAR-T therapy. The generation of positive data in these validated models of disease has the potential to open up highly valuable licensing and partnering opportunities for Avacta in this therapy area which has attracted so much attention in the past couple of years."
Trader4Pay
Posts: 33
Off Topic
Opinion:No Opinion
Price:101.00
Buy opportunity
18 Aug '16
Selling is just dumb right now but I guess that's what makes a market
DD77
Posts: 180
Off Topic
Opinion:No Opinion
Price:109.00
Grant
10 Aug '16
That's quite a significant grant of £3.8 million. All helps with the development, can see this going from strength to strength now.......
DD77
Posts: 180
Off Topic
Opinion:No Opinion
Price:109.00
Grant
10 Aug '16
That's quite a significant grant of £3.8 million. All helps with the development, can see this going from strength to strength now.......




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.